probiome Sign in
← Conditions CancersKidney, urinary and reproductive Genus-level

Kidney cancer (renal cell carcinoma)

Compared within 1 study that had both: 51 people with kidney cancer (renal cell carcinoma) and 40 healthy people. 7 genera are less common in people with kidney cancer (renal cell carcinoma), and 37 more common.

A difference is an association: it doesn’t mean these genera cause, prevent or treat kidney cancer (renal cell carcinoma). GMrepo reports this group at the genus level only, so these are genera, not species.

Phylum

Searching opens both lists and shows only matching rows.

Less common in kidney cancer (renal cell carcinoma) · 7

Strongest first, then the biggest gap · Each figure is 10 people Strongest first · Each figure is 10 people
  1. Colidextribacter genus in 1 study Healthy 100% kidney cancer (renal cell carcinoma) 26%
  2. Holdemania genus in 1 study Healthy 85% kidney cancer (renal cell carcinoma) 35%
  3. Merdimmobilis genus in 1 study Healthy 53% kidney cancer (renal cell carcinoma) 7.8%
  4. Oscillibacter genus in 1 study Healthy 100% kidney cancer (renal cell carcinoma) 77%
  5. Allofournierella genus in 1 study Healthy 43% kidney cancer (renal cell carcinoma) 7.8%

More common in kidney cancer (renal cell carcinoma) · 37

Strongest first, then the biggest gap · Each figure is 10 people Strongest first · Each figure is 10 people
  1. Microbacterium genus in 1 study Healthy 0% kidney cancer (renal cell carcinoma) 41%
  2. Paenibacillus genus in 1 study Healthy 0% kidney cancer (renal cell carcinoma) 37%
  3. Haliangium genus in 1 study Healthy 0% kidney cancer (renal cell carcinoma) 35%
  4. Bryobacter genus in 1 study Healthy 0% kidney cancer (renal cell carcinoma) 33%
  5. Gemmatimonas genus in 1 study Healthy 0% kidney cancer (renal cell carcinoma) 33%

Where these numbers come from

Studies
Only GMrepo projects that had people with the condition and healthy people, 10 or more of each. Numbers come from those studies, never from pooling.Sampled in China.
How common
The share of people whose sample has any of it, in the people with the condition and in the healthy people of those same studies. Tested within studies (Cochran–Mantel–Haenszel, corrected for testing many microbes); a difference counts when it is clear and meaningful (Cohen’s h of 0.2 or more).
Strength word
Counted by code from how many studies point the same way: Seen again and again (3 or more, none clearly the other way), Seen more than once (2, the majority), Seen once (1, listed last). Where studies disagree, a row isn’t listed.
Each study
Tap a row for every study’s own numbers, and for how much carriers have.
Analysis
Our analysis of GMrepo data. GMrepo on Data sources · Read the rules

Also compared · 96 genera

Compared within studies that had both, but not listed above.

No meaningful difference · 96
PubMed · human studies and reviews first

Recent research

All research on it
  1. Systematic review World journal of urology · 2026
    Gut microbiome impact on systemic therapy outcomes in metastatic renal cell carcinoma: a systematic review.
    PubMed ↗
  2. Meta-analysis Urologiia · 2026
    [Microbiome as a Novel Player in the Development and Treatment of Renal Cancer: A Systematic Review and Meta-Analysis].
    PubMed ↗
  3. Clinical trial Nature medicine · 2026
    Fecal microbiota transplantation plus immunotherapy in metastatic renal cell carcinoma: the phase 1 PERFORM trial.
    PubMed ↗
  4. Review European urology focus · 2025
    Clinical Applications of Microbiome in Renal Cell Carcinoma.
    PubMed ↗
  5. Animal study Scientific reports · 2023
    An oral cancer vaccine using Bifidobacterium vector augments combination of anti-PD-1 and anti-CTLA-4 antibodies in mouse renal cell carcinoma model.
    PubMed ↗

Source: PubMed, U.S. National Library of Medicine · 8 linked papers, last 10 years